Drug Profile
Research programme: breast cancer therapy - Biogen Idec/PDL BioPharma
Latest Information Update: 03 Jul 2006
Price :
$50
*
At a glance
- Originator Biogen Idec; PDL BioPharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 03 Jul 2006 No development reported - Preclinical for Breast cancer in USA (unspecified route)
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec